New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
How does T-cell acute lymphoblastic leukaemia go to the brain?
Identifying drivers of central nervous system involvement in T-cell acute lymphoblastic leukaemia
Exploring a novel drug treatment for osteosarcoma
Drug repurposing targeting immunomodulatory Haem oxygenase-1 (HO-1) for prevention of osteosarcoma growth and metastasis
Developing a ‘biodegradable paste’ to deliver chemotherapy directly to the brain to treat childhood brain tumours
Neurosurgically-applied chemotherapy for childhood brain tumours arising in the posterior fossa using a biodegradable paste
The Little Princess Trust Knowledge Bank of Wilms Tumour
The Little Princess Trust Knowledge Bank of Wilms Tumour
Factors which affect survival following relapse in neuroblastomas
Clinical and biological factors associated with relapse and length of survival following relapse in UK neuroblastomas
Phase II clinical trial: Testing a new therapy to treat children with relapsed/ refractory cancers and immune system over-activation conditions
GOTHAM - A phase II trial to assess the activity of Gemtuzumab Ozogamicin Therapy in HAemophagocytic lymphohistiocytosis (HLH)/Macrophage activation syndrome (MAS) or relapsed/refractory cancers
Improving our understanding of immunotherapy in high-risk neuroblastoma
Understanding and improving the mechanism of action of anti-GD2 monoclonal antibody therapy in neuroblastoma
‘Starving’ brain tumours to death
Exploring alterations in amino acid metabolism as novel therapeutic targets in paediatric glial tumours using advanced metabolomics methods